Details

Autor(en) / Beteiligte

• Chitwood, W. Randolph, MD
• Rodriguez, Evelio, MD
• Chu, Michael W.A., MD
• Hassan, Ansar, MD, PhD
• Ferguson, T. Bruce, MD
• Vos, Paul W., PhD
• Nifong, L. Wiley, MD

Titel

Robotic mitral valve repairs in 300 patients: A single-center experience

Ist Teil von

• The Journal of thoracic and cardiovascular surgery, 2008-08, Vol.136 (2), p.436-441

Ort / Verlag

Philadelphia, PA: Elsevier Inc

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Objectives Mitral valve repair is the standard therapy for patients with degenerative (myxomatous) disease and severe mitral regurgitation. Robotic mitral valve repair provides the least-invasive surgical approach. We report the largest single-center robotic mitral valve repair experience. Methods Between May 2000 and November 2006, 300 patients underwent a robotic mitral valve repair (daVinci Surgical System; Intuitive Surgical, Inc, Sunnyvale, Calif). All operations were done with 3- to 4-cm right intercostal access, transthoracic aortic occlusion, and peripheral cardiopulmonary bypass. Repairs included 1 or a combination of trapezoidal/triangular leaflet resections, sliding plasties, chordal transfers/replacements, edge-to-edge approximations, and ring annuloplasties. Echocardiographic and survival follow-up were 93% and 100% complete, respectively. Results There were 2 (0.7%) 30-day mortalities and 6 (2.0%) late mortalities. No sternotomy conversions or mitral valve replacements were required. Immediate postrepair echocardiograms showed the following degrees of mitral regurgitation: none/trivial, 294 (98%); mild, 3 (1.0%); moderate, 3 (1.0%); and severe, 0 (0.0%). Complications included 2 (0.7%) strokes, 2 transient ischemic attacks, 3 (1.0%) myocardial infarctions, and 7 (2.3%) reoperations for bleeding. The mean hospital stay was 5.2 ± 4.2 (standard deviation) days. Sixteen (5.3%) patients required a reoperation. Mean postoperative echocardiographic follow-up at 815 ± 459 (standard deviation) days demonstrated the following degrees of mitral regurgitation: none/trivial, 192 (68.8%); mild, 66 (23.6%); moderate, 15 (5.4%); and severe, 6 (2.2%). Five-year Kaplan–Meier survival was 96.6% ± 1.5%, with 93.8% ± 1.6% freedom from reoperation. Conclusions Robotic mitral valve repair is safe and is associated with good midterm durability. Further long-term follow-up is necessary.